Formycon AG Total Liabilities
Formycon AG total liabilities. Based on the latest financial reports, Formycon AG (FYB) has total liabilities worth €340.39 Million EUR (≈ $397.95 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Formycon AG's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Formycon AG (2009–2025)
Total liabilities of Formycon AG from 2009 to 2025. This chart illustrates how Formycon AG's total liabilities have evolved over time, based on quarterly financial data. Explore Formycon AG (FYB) investment intensity to see how much of total assets are deployed in long-term investments.
Formycon AG Competitors by Total Liabilities
The table below lists competitors of Formycon AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MT Hoejgaard Holding A/S
CO:MTHH
|
Denmark | Dkr2.80 Billion |
|
Yunnan Jinggu Forestry Co Ltd
SHG:600265
|
China | CN¥126.11 Million |
|
Fujian Jinsen Forestry Co Ltd
SHE:002679
|
China | CN¥1.22 Billion |
|
China Railway Prefabricated Construction Co Ltd
SHE:300374
|
China | CN¥3.58 Billion |
|
Shenzhen Magic Design & Decoration Engineering Co Ltd
SHE:002856
|
China | CN¥1.17 Billion |
|
Aduro Clean Technologies Inc. Common Stock
NASDAQ:ADUR
|
USA | $18.35 Million |
|
Shenzhen Bioeasy Biotechnology Co. Ltd.
SHE:300942
|
China | CN¥588.54 Million |
|
Zhejiang East Crystal Electronic Co Ltd
SHE:002199
|
China | CN¥257.97 Million |
Liability Composition Analysis (2009–2025)
This chart breaks down Formycon AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see FYB asset base.
Liquidity & Leverage Metrics
Formycon AG Total Liabilities Ratios Explained
Formycon AG total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Formycon AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Formycon AG (2009–2025)
The table below shows the annual total liabilities of Formycon AG from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €340.39 Million ≈ $397.95 Million |
+9.85% |
| 2024-12-31 | €309.87 Million ≈ $362.27 Million |
-20.06% |
| 2023-12-31 | €387.61 Million ≈ $453.16 Million |
-22.03% |
| 2022-12-31 | €497.12 Million ≈ $581.18 Million |
+3253.46% |
| 2021-12-31 | €14.82 Million ≈ $17.33 Million |
+96.00% |
| 2020-12-31 | €7.56 Million ≈ $8.84 Million |
+41.51% |
| 2019-12-31 | €5.34 Million ≈ $6.25 Million |
-16.28% |
| 2018-12-31 | €6.38 Million ≈ $7.46 Million |
+20.82% |
| 2017-12-31 | €5.28 Million ≈ $6.18 Million |
+23.03% |
| 2016-12-31 | €4.29 Million ≈ $5.02 Million |
+88.68% |
| 2015-12-31 | €2.28 Million ≈ $2.66 Million |
-30.28% |
| 2014-12-31 | €3.26 Million ≈ $3.82 Million |
+2.22% |
| 2013-12-31 | €3.19 Million ≈ $3.73 Million |
-5.48% |
| 2012-12-31 | €3.38 Million ≈ $3.95 Million |
+639.50% |
| 2011-12-31 | €457.00K ≈ $534.28K |
+118.40% |
| 2010-12-31 | €209.25K ≈ $244.64K |
+243.03% |
| 2009-12-31 | €61.00K ≈ $71.32K |
-- |
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well… Read more